Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO – Get Free Report) have been given a consensus recommendation of “Buy” by the nine research firms that are presently covering the firm, MarketBeat Ratings reports. Eight equities research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $22.14.
LXEO has been the subject of a number of research analyst reports. Royal Bank of Canada reaffirmed an “outperform” rating and set a $24.00 price objective on shares of Lexeo Therapeutics in a report on Tuesday, August 13th. Chardan Capital reiterated a “buy” rating and set a $23.00 target price on shares of Lexeo Therapeutics in a research report on Wednesday, August 14th. HC Wainwright lowered their target price on Lexeo Therapeutics from $22.00 to $21.00 and set a “buy” rating for the company in a research report on Tuesday, August 13th. Robert W. Baird initiated coverage on Lexeo Therapeutics in a research report on Thursday, June 13th. They set an “outperform” rating and a $28.00 target price for the company. Finally, Baird R W upgraded Lexeo Therapeutics to a “strong-buy” rating in a research report on Thursday, June 13th.
Read Our Latest Stock Report on Lexeo Therapeutics
Insider Buying and Selling
Institutional Trading of Lexeo Therapeutics
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Bank of New York Mellon Corp increased its stake in Lexeo Therapeutics by 12.3% in the second quarter. Bank of New York Mellon Corp now owns 31,806 shares of the company’s stock worth $510,000 after purchasing an additional 3,483 shares during the period. Rhumbline Advisers increased its stake in Lexeo Therapeutics by 37.3% in the second quarter. Rhumbline Advisers now owns 13,357 shares of the company’s stock worth $214,000 after purchasing an additional 3,627 shares during the period. BNP Paribas Financial Markets purchased a new stake in Lexeo Therapeutics in the first quarter worth $75,000. American International Group Inc. purchased a new stake in Lexeo Therapeutics in the first quarter worth $79,000. Finally, Vanguard Group Inc. increased its stake in Lexeo Therapeutics by 15.8% in the first quarter. Vanguard Group Inc. now owns 481,755 shares of the company’s stock worth $7,554,000 after purchasing an additional 65,573 shares during the period. Hedge funds and other institutional investors own 60.67% of the company’s stock.
Lexeo Therapeutics Trading Down 0.8 %
Shares of LXEO opened at $9.59 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.38 and a quick ratio of 9.38. Lexeo Therapeutics has a 1 year low of $9.00 and a 1 year high of $22.33. The company has a 50 day simple moving average of $12.07 and a two-hundred day simple moving average of $13.79. The firm has a market cap of $315.94 million and a P/E ratio of -0.43.
Lexeo Therapeutics (NASDAQ:LXEO – Get Free Report) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.64) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.64). On average, equities analysts expect that Lexeo Therapeutics will post -2.74 earnings per share for the current fiscal year.
Lexeo Therapeutics Company Profile
Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.
Featured Articles
- Five stocks we like better than Lexeo Therapeutics
- What is the Hang Seng index?
- Palo Alto Analysts Drive it to New Highs: 50% Upside Is Possible
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Roblox’s Growth Beyond Kids: Stock Set for Major Moves
- How to Read Stock Charts for Beginners
- 5 Oversold Stocks to Buy Right Now
Receive News & Ratings for Lexeo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexeo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.